Iraqi Journal of Hematology

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 7  |  Issue : 2  |  Page : 67--71

Treatment outcome of 100 chronic myeloid leukemia patients using nilotinib as the 2nd line therapy


Yaseen M Taher1, Ali M Almothaffar2, Bassam Francis Matti3, Alaa Fadhil Alwan4 
1 Department of Medicine, University of AL Iraqia/College of Medicine, Baghdad, Iraq
2 Department of Medicine, University of Baghdad/College of Medicine, Baghdad, Iraq
3 Department of Medicine, Hematology Unit, Baghdad Teaching Hospital, Baghdad, Iraq
4 The National Center of Hematology, Mustansiriyah University, Baghdad, Iraq

Correspondence Address:
Dr. Yaseen M Taher
Department of Medicine, College of Medicine, Al Iraqia University, Baghdad
Iraq

Background: Nilotinib is a potent and selective BCR-ABL inhibitor approved for use in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) and in patients with CML-CP and accelerated phase (CML-AP) who are resistant to or intolerant of imatinib. Patients with imatinib-resistant CML, nilotinib treatment resulted in a significant proportion of patients achieving hematologic and cytogenetic responses in all phases of CML. Objectives: The aim of the present study was to assess the treatment outcomes in term of the molecular response rate of CML patients using Nilotinib as the second-line therapy after failure of imatinib therapy. Patients and Methods: A prospective study conducted between December 2014 and December 2016 in Baghdad Teaching Hospital and National Centre of hematology. A total of 100 patients, who were on nilotinib therapy as the second-line therapy, were enrolled in this study. The molecular response was assessed using real-time quantitative polymerase chain reaction (RQ-PCR). Major molecular response (MMR) was defined as the BCR-ABL1 of <0.1% by RQ-PCR. Results: The median age was 39 years, 59 were female and 41 were male. Fifty-three patients were classified as high-risk group, and 47 patients were as low risk. The BCR-ABL transcription level had a significant reduction from baseline at 3 months (P = 0.035) and the reduction from 3 months to 6 months was also statistically significant (P < 0.001). Comparing the patients who achieved MMR versus NO MMR, there was a significant association between low European Treatment and Outcome Study score and achieving MMR. An estimated 24 months overall survival (OS) is 95%. Conclusion: This study concluded that nilotinib is an effective therapeutic option for patients with CML-CP-resistant to imatinib therapy. Nilotinib treatment resulted in a high-OS rate and was well tolerated.


How to cite this article:
Taher YM, Almothaffar AM, Matti BF, Alwan AF. Treatment outcome of 100 chronic myeloid leukemia patients using nilotinib as the 2nd line therapy.Iraqi J Hematol 2018;7:67-71


How to cite this URL:
Taher YM, Almothaffar AM, Matti BF, Alwan AF. Treatment outcome of 100 chronic myeloid leukemia patients using nilotinib as the 2nd line therapy. Iraqi J Hematol [serial online] 2018 [cited 2020 Jul 5 ];7:67-71
Available from: http://www.ijhonline.org/article.asp?issn=2072-8069;year=2018;volume=7;issue=2;spage=67;epage=71;aulast=Taher;type=0